Aspen posts growth on ex-S. Africa expansion; FDA clears Teva's Jerusalem plant;

@FiercePharma: RT @reutersBenHir: #Novartis talks up Alcon (up to low-double digit growth + $350M synergies) as development head jumps to Gates Foundation. | Follow @FiercePharma

> GlaxoSmithKline ($GSK) partner Aspen Pharmacare posted a 20% increase in full-year profits, as revenues and profits from markets outside South Africa exceeded domestic numbers for the first time. News

> Teva Pharmaceutical Industries said the FDA has cleared its Jerusalem plant, which had been cited in January for manufacturing violations, after a reinspection of the facility. Story

> Medicis Pharmaceutical agreed to sell its technologies unit, which recently won approval for the Liposonix device, to Solta for $15 million. Item

> An analyst hiked sales projections for Optimer Pharmaceuticals' C. difficile treatment Dificid, sending shares up. Article

> GlaxoSmithKline sued Impax Laboratories, which is working toward a knock-off version of GSK's prostate drug Jalyn. News

> Prescription drugs in Australia are among the most expensive in the world, a new study has found. Story

> The Scottish Medicines Consortium approved Celgene's Vidaza for use in patients with advanced myelodysplastic syndromes after the company proposed a patient access scheme. Article

> People who regularly use painkillers similar to ibuprofen and naproxen may be run a higher risk of kidney cancer. Report

> According to a new study, statins appear safe to use after stroke; data suggested use of the drugs does not increase the risk of brain bleeding. News

> Two meta-analyses found that lifestyle changes and statin therapy not only improved cardiovascular risk factors, but also led to better sexual function in men. Item

Biotech News

@FierceBiotech: Novartis hasn't cut R&D spend, unlike some drugmakers. Has logged 17 new drug approvals over the past 1.5 years in U.S., Europe | Follow @FierceBiotech

@JohnCFierce: Dutch biotech AM-Pharma raises €29.2 million in D round. Report | Follow @JohnCFierce

@RyanMFierce: Kiwi firm (not fruit) Biomatters, which sells scientific software, has opened its first U.S. offices in NJ and CA. Item | Follow @RyanMFierce

@MaureenFierce: Pharma hiring on the rise for the fourth quarter in a row. Story | Follow @MaureenFierce

> On a winning streak, Novartis maps bullish ophthalmology R&D strategy. Article 

> Termeer launches cancer research center with $10M in seed cash. Story

Biotech Research News

> From a poisonous crocus, comes an anti-cancer smart bomb. News

> Drugs in search of LTR with right protein. Report

> New obesity drugs will tell the brain that enough is enough. Article 

> Green-glowing cats light the way to possible new AIDS treatment. News

> Embryonic, induced pluripotent stem cells found to be similar. Report 

Manufacturing News

> Survey: Pharma hiring on the rise. Story

> iPad can be lean enabler in hands of execs. Article

> Patheon reveals strategy amid poor financials. Report 

> German trial a step toward upcoming track/trace mandate. News

> Roche tops DJ healthcare sustainability index. Story

And Finally... A small study suggests that an insulin nasal spray may help delay Alzheimer's disease; researchers caution that follow-up is needed. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.